|
1
|
Petrikkos G, Skiada A, Lortholary O,
Roilides E, Walsh TJ and Kontoyiannis DP: Epidemiology and clinical
manifestations of mucormycosis. Clin Infect Dis. 54 (Suppl
1):S23–S34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kauffman CA: Zygomycosis: Reemergence of
an old pathogen. Clin Infect Dis. 39:588–590. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaezi A, Moazeni M, Rahimi MT, de Hoog S
and Badali H: Mucormycosis in Iran: A systematic review. Mycoses.
59:402–415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jeong W, Keighley C, Wolfe R, Lee WL,
Slavin MA, Kong DCM and Chen SC: The epidemiology and clinical
manifestations of mucormycosis: A systematic review and
meta-analysis of case reports. Clin Microbiol Infect. 25:26–34.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kursun E, Turunc T, Demiroglu YZ, Aliskan
HE and Arslan AH: Evaluation of 28 cases of mucormycosis. Mycoses.
58:82–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Serris A, Danion F and Lanternier F:
Disease entities in mucormycosis. J Fungi (Basel). 5(pii): E232019.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roden MM, Zaoutis TE, Buchanan WL, Knudsen
TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH,
et al: Epidemiology and outcome of zygomycosis: A review of 929
reported cases. Clin Infect Dis. 41:634–653. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andrey DO, Kaiser L, Emonet S, Erard V,
Chalandon Y and van Delden C: Cerebral Rhizomucor infection treated
by Posaconazole delayed-release tablets in an allogeneic stem cell
transplant recipient. Int J Infect Dis. 55:24–26. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xipell M, Losno RA, Garcia-Vidal C, Rovira
M, Alejo-Cancho I, Puig de la Bellacasa J, López M, Cardozo C,
Bodro M, Mensa J and Soriano A: Clinical features and outcome in
patients with mucormycosis in a tertiary hospital (2012–2016). Rev
Iberoam Micol. 35:162–166. 2018.(In Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Posteraro B, Spanu T, Fiori B, De Maio F,
De Carolis E, Giaquinto A, Prete V, De Angelis G, Torelli R,
D'Inzeo T, et al: Antifungal susceptibility profiles of bloodstream
yeast isolates by Sensititre YeastOne over nine years at a large
Italian teaching hospital. Antimicrob Agents Chemother.
59:3944–3955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clinical and Laboratory Standards
Institute (CLSI) M38, . Reference method for broth dilution
antifungal susceptibility testing of filamentous Fungi. 3rd. CLSI;
Wayne, PA: 2017, https://clsi.org/standards/products/microbiology/documents/m38/November
30–2017
|
|
12
|
Kennedy KJ, Daveson K, Slavin MA, van Hal
SJ, Sorrell TC, Lee A, Marriott DJ, Chapman B, Halliday CL,
Hajkowicz K, et al: Mucormycosis in Australia: Contemporary
epidemiology and outcomes. Clin Microbiol Infect. 22:775–781. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Long B and Koyfman A: Mucormycosis: What
emergency physicians need to know? Am J Emerg Med. 33:1823–1825.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ville S, Talarmin JP, Gaultier-Lintia A,
Bouquié R, Sagan C, Le Pape P, Giral M and Morio F: Disseminated
mucormycosis with cerebral involvement owing to rhizopus
microsporus in a kidney recipient treated with combined liposomal
amphotericin B and posaconazole therapy. Exp Clin Transplant.
14:96–99. 2016.PubMed/NCBI
|
|
15
|
Chamilos G, Marom EM, Lewis RE, Lionakis
MS and Kontoyiannis DP: Predictors of pulmonary zygomycosis versus
invasive pulmonary aspergillosis in patients with cancer. Clin
Infect Dis. 41:60–66. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bitar D, Van Cauteren D, Lanternier F,
Dannaoui E, Che D, Dromer F, Desenclos JC and Lortholary O:
Increasing incidence of zygomycosis (mucormycosis), France,
1997–2006. Emerg Infect Dis. 15:1395–1401. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cornely OA, Arikan-Akdagli S, Dannaoui E,
Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada
A, Akova M, et al: ESCMID and ECMM joint clinical guidelines for
the diagnosis and management of mucormycosis 2013. Clin Microbiol
Infect. 20 (Suppl 3):S5–S26. 2014. View Article : Google Scholar
|
|
18
|
Lin E, Moua T and Limper AH: Pulmonary
mucormycosis: Clinical features and outcomes. Infection.
45:443–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Q, Liu B and Yan Y: Disseminated
mucormycosis (DM) after pneumonectomy: A case report. BMC Infect
Dis. 16:3372016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Walsh TJ, Gamaletsou MN, McGinnis MR,
Hayden RT and Kontoyiannis DP: Early clinical and laboratory
diagnosis of invasive pulmonary, extrapulmonary and disseminated
mucormycosis (zygomycosis). Clin Infect Dis. 54 (Suppl 1):S55–S60.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paul SR and Gable PS: Mucormycosis as the
elusive cause of an aortic thrombus and tissue-obliterating
abscess. Case Rep Hematol. 2019:48421502019.PubMed/NCBI
|
|
22
|
Song Y, Qiao J, Giovanni G, Liu G, Yang H,
Wu J and Chen J: Mucormycosis in renal transplant recipients:
Review of 174 reported cases. BMC Infect Dis. 17:2832017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iwen PC, Freifeld AG, Sigler L and
Tarantolo SR: Molecular identification of Rhizomucor pusillus as a
cause of sinus-orbital zygomycosis in a patient with acute
myelogenous leukemia. J Clin Microbiol. 43:5819–5821. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dannaoui E, Meletiadis J, Mouton JW, Meis
JF and Verweij PE; Eurofung Network, : In vitro susceptibilities of
zygomycetes to conventional and new antifungals. J Antimicrob
Chemother. 51:45–52. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Multani A, Reveron-Thornton R, Garvert DW,
Gomez CA, Montoya JG and Lui NS: Cut it out! Thoracic Surgeon's
approach to pulmonary mucormycosis and the role of surgical
resection in survival. Mycoses. 62:893–907. 2019. View Article : Google Scholar : PubMed/NCBI
|
